PRESS RELEASE published on 09/10/2025 at 05:50, 5 months 10 days ago Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 Lobe Sciences Ltd. to participate in Clusterbusters 20th Annual U.S. Patient Conference to highlight psilocin treatment for cluster headaches and discuss funding success for further research and development Patient Advocacy Conjugated Psilocin Chronic Cluster Headaches Lobe Sciences Ltd. Clusterbusters Conference
BRIEF published on 09/09/2025 at 05:55, 5 months 11 days ago Lobe Sciences nomme Marco Mastrodonato à son conseil d'administration Biopharmaceutique Nomination Au Conseil D'administration Développement Thérapeutique Sciences Du Lobe Marco Mastrodonato
BRIEF published on 09/09/2025 at 05:55, 5 months 11 days ago Lobe Sciences Appoints Marco Mastrodonato to Board Biopharmaceutical Board Appointment Therapeutic Development Lobe Sciences Marco Mastrodonato
PRESS RELEASE published on 09/09/2025 at 05:50, 5 months 11 days ago Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors Lobe Sciences Ltd. appoints Marco Mastrodonato to its Board of Directors, bringing extensive experience in pharmaceutical and biotechnology industries, enhancing global business acumen Board Of Directors Pharmaceutical Industry Lobe Sciences Ltd. Marco Mastrodonato Biotechnology Industry
BRIEF published on 08/15/2025 at 05:05, 6 months 5 days ago Lobe Sciences conclut un placement privé pour lever 341 425 $ CA Placement Privé Biopharmaceutique Offre D'actions Marché Canadien Sciences Du Lobe
BRIEF published on 08/15/2025 at 05:05, 6 months 5 days ago Lobe Sciences Concludes Private Placement to Raise CAD $341,425 Private Placement Canadian Market Biopharmaceutical Equity Offering Lobe Sciences
PRESS RELEASE published on 08/15/2025 at 05:00, 6 months 5 days ago Lobe Sciences Announces the Closing of the Previously Announced Private Placement Lobe Sciences completes non-brokered private placement totaling $341,425 CAD. Securities subject to statutory holding period. Developing treatments for rare diseases Private Placement Biopharmaceutical Therapeutics Rare Diseases Lobe Sciences
BRIEF published on 07/29/2025 at 06:15, 6 months 22 days ago Lobe Sciences annonce un placement privé pour le financement des entreprises Placement Privé Investissements Biopharmaceutique Financement Des Entreprises Sciences Du Lobe
BRIEF published on 07/29/2025 at 06:15, 6 months 22 days ago Lobe Sciences Announces Private Placement for Corporate Funding Private Placement Biopharmaceutical Investments Corporate Funding Lobe Sciences
BRIEF published on 07/29/2025 at 06:13, 6 months 22 days ago Lobe Sciences Ltd. s'associe à ArcStone pour sa stratégie de marché Partenariat Stratégique Biopharmaceutique Marchés Financiers Relations Avec Les Investisseurs Positionnement Sur Le Marché
Published on 02/20/2026 at 20:15, 1 hour 25 minutes ago Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 1 hour 25 minutes ago Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 3 hours 10 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 5 hours 55 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 7 hours 10 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 18:36, 3 hours 3 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 3 hours 8 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 3 hours 39 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 3 hours 39 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 19:29, 2 hours 10 minutes ago SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 2 hours 10 minutes ago SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 3 hours 40 minutes ago TERACT - Résiliation du contrat de liquidité
